These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 28430623

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).
    Hu X, Han B, Gu A, Zhang Y, Jiao SC, Wang CL, He J, Jia X, Zhang L, Peng J, Wu M, Ying K, Wang J, Ma K, Zhang S, You C, Tan F, Wang Y, Ding L, Sun Y.
    Lung Cancer; 2014 Nov; 86(2):207-12. PubMed ID: 25261231
    [Abstract] [Full Text] [Related]

  • 5. Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer.
    Ren GJ, Zhao YY, Zhu YJ, Xiao Y, Xu JS, Shan B, Zhang L.
    Chin Med J (Engl); 2011 Jan; 124(1):19-25. PubMed ID: 21362302
    [Abstract] [Full Text] [Related]

  • 6. Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study.
    Yang W, Gao Y, Li X, Zhang J, Liu T, Feng X, Pan H, Yang X, Xie S, Feng X, Lv Z, Wang Y, Chen Z, He J.
    World J Surg Oncol; 2017 Nov 06; 15(1):197. PubMed ID: 29110716
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies.
    Biaoxue R, Hua L, Wenlong G, Shuanying Y.
    Oncotarget; 2016 Dec 27; 7(52):86902-86913. PubMed ID: 27893423
    [Abstract] [Full Text] [Related]

  • 8. [Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified].
    Li X, Qin N, Wang J, Yang X, Zhang X, Lv J, Wu Y, Zhang H, Nong J, Zhang Q, Zhang S.
    Zhongguo Fei Ai Za Zhi; 2015 Dec 27; 18(12):734-9. PubMed ID: 26706949
    [Abstract] [Full Text] [Related]

  • 9. [Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified].
    Song Z, Yu X, Cai J, Shao L, Lin B, He C, Zhang B, Zhang Y.
    Zhongguo Fei Ai Za Zhi; 2013 Mar 27; 16(3):138-43. PubMed ID: 23514942
    [Abstract] [Full Text] [Related]

  • 10. Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial.
    Li X, Zhang L, Jiang D, Wang Y, Zang A, Ding C, Zhao M, Su W, Zhang Y, Zhong D, Wu J, Zhang C, An G, Hu X, Cheng G, Wang H, Li Y, He X, Liu J, Liang L, Ding L, Mao L, Zhang S.
    Clin Cancer Res; 2020 Jul 01; 26(13):3162-3171. PubMed ID: 32060099
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinicopathologic characteristics and outcome of patients with different EGFR mutations.
    Zhou S, Hu X, Wang Y, Li J, Zhou L, Hao X, Liu Y, Shi Y.
    Asia Pac J Clin Oncol; 2019 Jun 01; 15(3):166-171. PubMed ID: 30311393
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.
    Zhao Q, Shentu J, Xu N, Zhou J, Yang G, Yao Y, Tan F, Liu D, Wang Y, Zhou J.
    Lung Cancer; 2011 Aug 01; 73(2):195-202. PubMed ID: 21144613
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y, Maemondo M, Ishii Y, Okudera K, Demura Y, Takamura K, Kobayashi K, Morikawa N, Gemma A, Ishimoto O, Usui K, Harada M, Miura S, Fujita Y, Sato I, Saijo Y, North-East Japan Study Group.
    Lung Cancer; 2014 Nov 01; 86(2):195-200. PubMed ID: 25249428
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of icotinib in advanced lung squamous cell carcinoma.
    Liang S, Xu Y, Tan F, Ding L, Ma Y, Wang M.
    Cancer Med; 2018 Sep 01; 7(9):4456-4466. PubMed ID: 30109777
    [Abstract] [Full Text] [Related]

  • 20. Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis.
    Sheng M, Wang F, Zhao Y, Li S, Wang X, Shou T, Luo Y, Tang W.
    Eur J Clin Pharmacol; 2016 Jan 01; 72(1):1-11. PubMed ID: 26490356
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.